A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JX2105 in Healthy Chinese Subjects The Purpose of the Study is to Evaluate the Safety, Tolerability After Administration of Single Dose or Multiple Doses, and the Pharmacokinetics (PK) of Single and Multiple Doses of JX2105 in Healthy Study Participants.

Zhejiang Jingxin Pharmaceutical Co., Ltd.1 site in 1 country52 target enrollmentJuly 1, 2024

ConditionsParkinson's Disease

InterventionsJX2105 Placebo

Overview

Phase: Phase 1
Intervention: JX2105
Conditions: Parkinson's Disease
Sponsor: Zhejiang Jingxin Pharmaceutical Co., Ltd.
Enrollment: 52
Locations: 1
Primary Endpoint: TEAE/SAE
Status: Enrolling By Invitation
Last Updated: last year

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study is to evaluate the safety, tolerability after administration of single dose or multiple doses, and the pharmacokinetics (PK) of single and multiple doses of JX2105 in healthy study participants.

Detailed Description

Overall design: This study is divided into 3 parts: Part 1: single-dose escalation study (SAD); Part 2: multiple-dose escalation study (MAD); Part 3: food-effect study (FE). Part 1 includes 7 cohorts; Part 2 includes 2\~3cohorts; and Part 3 food effect study will conduct on 1 dose strength to evaluate the effect of food intake on pharmacokinetic/pharmacodynamics of JX2105 and its metabolites. The doses of part 2 and 3 will be designed according to the PK parameters from Part 1. Maximum recommended human dose of part 1 is 10 mg and the maximum dose is 180 mg.

Registry

clinicaltrials.gov

Start Date

July 1, 2024

End Date

March 2025

Last Updated

last year

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Zhejiang Jingxin Pharmaceutical Co., Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male and female healthy participant must be 18 to 75 years of age inclusive.
•Body mass index (BMI) within the range 18.5 to 28 kg/m\^2 (inclusive).
•Subjects must adhere to contraception restrictions from signing the informed consent to 3 months after the last dose.
•Willing to participate in the clinical trial and provide signed informed consent.

Exclusion Criteria

•Having a history or present condition of diseases or dysfunction that may affect the clinical trial on the consideration of investigator, including but not limited to central nervous system, cardiovascular system, respiratory system, digestive system, urinary system, endocrine system, blood system and other diseases;
•Having a history or present condition of mental illness;
•Any surgical condition or condition that could significantly affect the absorption, distribution, metabolism, and excretion of the investigational drug or could jeopardize the subjects participating in the trial; such as a history of gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, gastrointestinal ulcer, gastrointestinal bleeding, etc.;
•Usage of any drugs within 2 weeks before screening, including prescription drugs, over-the-counter drugs and Chinese herbal medicines;
•With a known history of allergy to investigational drug ingredients or similar drugs, history of allergic diseases or allergic constitution;
•Having clinical significance in laboratory test in the opinion of the Investigator, or creatinine clearance \< 80 mL/min;
•Having clinical significant electrocardiogram (ECG) abnormality and chest X-ray examination indicators, in the opinion of the Investigator;
•Having clinical significance in vital signs, with sitting resting pulse rate \< 50 beats/min or \> 100 beats/min; systolic blood pressure \< 90 mmHg or \> 140 mmHg; diastolic blood pressure \< 50 mmHg or \> 90 mmHg, in the opinion of the Investigator;
•Having one or more clinically significant tests for hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency virus antibody and treponema pallidum antibody;
•Female participant with positive pregnancy test results;